This retrospective study assessed the relationship between baseline axial length and subsequent elongation for myopes wearing orthokeratology lenses. The results showed axial elongation was slower over two years for younger children with longer baseline axial lengths. This may help in approaches to optimizing myopia control.
This editorial evaluated a range of single and multi-country clinical trials to examine the impact of race on treatment efficacy in myopia control. The authors found a similar slowing of axial elongation and myopia progression for East Asian and non-East Asian children across all studies.
A new study has shown that an ‘extra compression factor’ of 1D, which is essentially increasing the treatment target, improved myopia control outcomes for children wearing orthokeratology. This would seem to indicate a different approach is needed for myopia control, but delving into the study reveals the story is not that simple.
Repeated low-level red light (RLRL) therapy is showing impressive results for myopia control in children, with a two-year randomized controlled trial showing highly impressive results for slowing and even reversing axial elongation. While reported as safe, a new case report suggests otherwise. Read more about this red hot topic here.
Johnson & Johnson Vision’s intent to lead with science was on full show at the recent ARVO at New Orleans. We look at 5 abstracts they presented, providing you summaries and the abstracts on topics such as efficacy in myopia control, myopia calculators and subjective vision outcomes for children and teens in soft contact lens designs for myopia.
The LAMP2 study explored the efficacy of low-concentration atropine to delay the onset of myopia in at-risk children. The results found there was no significant difference between 0.01% atropine and the placebo, but 0.05% atropine was able to reduce myopia incidence and speed of myopic progression for pre-myopes.
This reanalysis of data from 2 clinical trials evaluated the relative risk of fast axial eye growth in children wearing ortho-k lenses. The results showed that although younger children (6-8 years) experienced faster eye growth than older children (9-12 years), they also benefitted more from ortho-k in slowing their progression when worn for a 2-year period.
This prospective observational study found that DIMS spectacle lenses, atropine 0.01% and the combination of the two all showed robust efficacy for myopia control in European children. The combination treatment showed slightly better refractive control than the mono-therapies, but axial length growth was similar in all treatment groups.
The first year data from the ongoing CYPRESS randomized clinical trial show that Diffusion Optics Technology (DOT) spectacle lenses can regulate contrast signals across the retina to reduce myopia progression in children aged 6-10 years, and are safe and effective to wear.
This retrospective cohort analysis showed that NaturalVue Multifocal 1 Day contact lens wear appears to result in a mean refractive myopia progression of less than 0.25D per year, based on available data. Some limited axial length data was also presented.
